Related Experiment Video
Updated: Sep 17, 2025
10:02
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
2.3K
Membrane-modified lipid nanoparticles for RNA delivery.
Chitran Roy Chowdhury1, Elise C Hoover1, Emily S Day1,2,3
1Department of Biomedical Engineering, University of Delaware, 590 Avenue 1743, Newark, DE 19713, USA.
Molecular Therapy. Methods & Clinical Development
|July 4, 2025
Summary
Cell-derived membrane modifications enhance lipid nanoparticles (LNPs) for improved ribonucleic acid (RNA) delivery beyond the liver. These advanced LNPs show promise for broader RNA-based therapeutic applications.
Area of Science:
- Biotechnology
- Molecular Biology
- Drug Delivery Systems
Background:
- Ribonucleic acid (RNA)-based therapies offer significant potential for treating diverse medical conditions.
- Unmodified RNA is unstable and requires carriers like lipid nanoparticles (LNPs) for effective delivery.
- Current LNPs predominantly target the liver, limiting applications for extrahepatic diseases.
Purpose of the Study:
- To review the advancements in membrane-modified LNPs for RNA delivery.
- To discuss critical design considerations for these novel delivery systems.
- To explore the clinical potential of enhanced RNA delivery strategies.
Main Methods:
- Modification of LNPs with cell-derived phospholipid membranes.
- Evaluation of altered biodistribution and cellular uptake of modified LNPs.
- Assessment of gene regulation efficiency and therapeutic outcomes.
Main Results:
- Membrane modification alters LNP biodistribution, improving extrahepatic delivery.
- Enhanced cellular entry and endosomal escape are observed with modified LNPs.
- Improved gene regulation potency and therapeutic efficacy are achieved.
Conclusions:
- Membrane-modified LNPs represent a promising strategy for overcoming LNP liver-targeting limitations.
- Optimized design of these systems is crucial for successful clinical translation.
- Further development could unlock the full therapeutic potential of RNA-based medicines.
More Related Videos
Related Concept Videos
01:23RNA Interference
26.5K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.5K
02:15Experimental RNAi
6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
01:25Nucleic Acid Structure
7.1K
The pentose sugar in DNA is deoxyribose, while in RNA the pentose sugar is ribose. The difference between the sugars is the presence of the hydroxyl group on the ribose's second carbon and a hydrogen on the deoxyribose's second carbon. The phosphate residue attaches to the hydroxyl group of the 5′ carbon of one sugar and the hydroxyl group of the 3′ carbon of the sugar of the next nucleotide, which forms a 5′ to 3′ phosphodiester linkage.
DNA Structure
DNA...
DNA Structure
DNA...
7.1K